Assessing Portal Hypertension With Methacetin Breath Test
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02143778 |
Recruitment Status :
Completed
First Posted : May 21, 2014
Results First Posted : September 19, 2019
Last Update Posted : December 20, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Patients With Compensated Liver Cirrhosis | Device: Methacetin Breath Test | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 246 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis |
Actual Study Start Date : | November 2014 |
Actual Primary Completion Date : | December 2018 |
Actual Study Completion Date : | January 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Compensated cirrhotic patients
A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
|
Device: Methacetin Breath Test
13C labelled methacetin solution for breath test monitoring |
- CSPH (Clinically Significant Portal Hypertension) [ Time Frame: 1 hour ]Clinically significant portal hypertension is defined as Hepatic Venous Pressure Gradient (HVPG)>=10mmHg, whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify CSPH and the agreement to the reference standard (HVPG) will be assessed in this study.
- Hepatic Venous Pressure Gradient (HVPG)>=12; Severe Portal Hypertension (SPH) [ Time Frame: 1 hour ]Hepatic Venous Pressure Gradient greater than 12 (SPH) is an indicator of bleeding varices. whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify SPH and the agreement to the reference standard (HVPG) will be assessed in this study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult men or women (>18 years of age)
- Known chronic liver disease with cirrhosis
- Europe: Indicated to undergo HVPG testing
- US: Consented for HVPG
- For patients treated with beta blockers: They have to be on a stable dose for at least 6 weeks prior to any study related tasks
- For patients who stopped their treatment with beta blockers: Their last dose should be at least 6 weeks prior to any study related tasks
Exclusion Criteria:
- Decompensated cirrhosis as clinically defined by the presence of ascites, hepatic encephalopathy, variceal bleeding or hepatorenal syndrome
- Renal failure (creatinine > 2.5 mg/dl)
- Known acute renal tubular disease Known hypotension (Systolic Pressure <100mmHg)
- Hypocoagulablity defined as PT >6 and INR >2.3.
- Congestive heart failure (assessed clinically as NIHA >2)
- Known pulmonary hypertension (right ventricular systolic pressure > 45 mm Hg)
- Uncontrolled diabetes mellitus (HBA1C >9.5gr%)
- Concurrent prednisone or immunosuppressive treatment, if therapy and/or response to treatment are not stable for at least 3 months.
- Documented or suspected hepatocellular carcinoma
- Gastric bypass surgery or extensive small bowel resection
- Total parenteral nutrition
- Any organ transplant recipient
- Pregnant or breast feeding
- Allergy to acetaminophen and/or other related medications
- Documented drug-related concurrent hepatotoxicity or drug-related silent steatosis or drug-related fibrosis (e.g. amiodarone, methotrexate and tamoxifen)
- Uncontrolled malabsorption or diarrhea
- Documented non-cirrhotic PHT, partial / complete portal venous occlusion, hepatic venous occlusion, previous PHT surgery, or placement of a transjugular intrahepatic portosystemic shunt (TIPS)
- Primary or secondary biliary cirrhosis, primary or secondary sclerosing cholangitis, hepatic sarcoidosis, or other cholestatic disorders
- Subjects unable to perform the MBT within 7 days of HVPG procedure.
- Subject should not have taken any of the following for at least 48 hours prior to the breath test: Acyclovir , allopurinol, amiodarone, carbamazepine, cimetidine, ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or oral contraceptives or any medication that might interfere with Methacetin metabolism or might affect CYP 1A2
- Subject should not have taken amiodarone or statins within the last 30 days prior to the breath test or HVPG procedure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02143778
United States, Connecticut | |
VA Connecticut HealthCare System | |
New Haven, Connecticut, United States, 06516 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Virginia | |
Virginia Commonwealth University | |
Richmond, Virginia, United States, 23298 | |
France | |
Hôpital Beaujon | |
Paris, France | |
Hopital Purpan | |
Toulouse, France | |
Spain | |
(University of Barcelona) Hospital Clinic | |
Barcelona, Spain | |
Hospital Universitario Ramón y Cajal | |
Madrid, Spain | |
Switzerland | |
Inselspital | |
Bern, Switzerland, 3010 |
Principal Investigator: | Juan Carlos Garcia Pagan, MD | University Hospital Barcelona |
Documents provided by Meridian Bioscience, Inc.:
Responsible Party: | Meridian Bioscience, Inc. |
ClinicalTrials.gov Identifier: | NCT02143778 |
Other Study ID Numbers: |
CSPH-EX-4014 2014-002037-59 ( EudraCT Number ) |
First Posted: | May 21, 2014 Key Record Dates |
Results First Posted: | September 19, 2019 |
Last Update Posted: | December 20, 2022 |
Last Verified: | December 2022 |
MBT CSPH HVPG |
Liver Cirrhosis Hypertension, Portal Hypertension Fibrosis Vascular Diseases |
Cardiovascular Diseases Pathologic Processes Liver Diseases Digestive System Diseases |